A
1.36
0.03 (2.65%)
| Previous Close | 1.32 |
| Open | 1.35 |
| Volume | 1,539,732 |
| Avg. Volume (3M) | 1,885,193 |
| Market Cap | 360,624,160 |
| Price / Sales | 7.18 |
| Price / Book | 1.38 |
| 52 Weeks Range | |
| Earnings Date | 27 Mar 2026 |
| Operating Margin (TTM) | -726.31% |
| Diluted EPS (TTM) | -0.880 |
| Quarterly Revenue Growth (YOY) | -11.00% |
| Total Debt/Equity (MRQ) | 83.84% |
| Current Ratio (MRQ) | 9.24 |
| Operating Cash Flow (TTM) | -241.32 M |
| Levered Free Cash Flow (TTM) | -214.39 M |
| Return on Assets (TTM) | -20.27% |
| Return on Equity (TTM) | -49.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Autolus Therapeutics plc | Bearish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.25 |
|
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 18.09% |
| % Held by Institutions | 90.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Syncona Portfolio Ltd | 31 Dec 2025 | 16,640,720 |
| Tetragon Partners Gp Ltd | 31 Dec 2025 | 9,500,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (Needham, 638.01%) | Buy |
| Median | 9.50 (601.11%) | |
| Low | 9.00 (HC Wainwright & Co., 564.21%) | Buy |
| Average | 9.50 (601.11%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Feb 2026 | 9.00 (564.21%) | Buy | 1.51 |
| Needham | 12 Jan 2026 | 10.00 (638.01%) | Buy | 1.50 |
| 29 Dec 2025 | 11.00 (711.81%) | Buy | 1.87 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Announcement | Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 |
| 06 Jan 2026 | Announcement | Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform |
| 06 Jan 2026 | Announcement | Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |